礼来公司因每周一次的胰岛素产品获得FDA认可Onswik

2026-09-24 19:07

Eli Lilly (LLY) on Thursday announced that the U.S. FDA approved its once-weekly basal insulin product, Onswik, for adults with type 2 diabetes to be used with diet and exercise for the control of high blood sugar.
The decision is supported by data from the company’s QWINT Phase 3 clinical trials in which Onswik reached the primary endpoint, showing a comparable efficacy level to once-daily insulin products, insulin glargine U-100 (glargine), or insulin degludec U-100 (degludec).
According to the Indiana-based pharma giant, Onswik has the potential to cut more than 300 insulin injections annually compared with once-daily basal insulin. The decision marked the fourth global regulatory action favoring the product after similar approvals in Europe, Mexico, and Japan.
The company expects to launch Onswik in the coming months in two concentrations: 500 units/mL and 1,000 units/mL.

More on Eli Lilly